Stock analysts at Jefferies Financial Group began coverage on shares of Fate Therapeutics (NASDAQ:FATE – Get Free Report) in a report issued on Tuesday. The firm set a “buy” rating on the biopharmaceutical company’s stock.
Other research analysts have also issued research reports about the stock. HC Wainwright raised their price objective on shares of Fate Therapeutics from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Monday, May 4th. Weiss Ratings raised Fate Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, May 13th. Three investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $5.50.
Read Our Latest Report on Fate Therapeutics
Fate Therapeutics Price Performance
Fate Therapeutics (NASDAQ:FATE – Get Free Report) last issued its earnings results on Wednesday, May 13th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.03. The business had revenue of $1.30 million for the quarter, compared to analyst estimates of $1.49 million. Fate Therapeutics had a negative net margin of 2,056.79% and a negative return on equity of 58.89%. On average, research analysts predict that Fate Therapeutics will post -1.08 earnings per share for the current year.
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in the company. Commonwealth Equity Services LLC bought a new position in shares of Fate Therapeutics in the fourth quarter valued at approximately $26,000. Bridgeway Capital Management LLC bought a new position in Fate Therapeutics in the 2nd quarter valued at $28,000. Corient Private Wealth LLC purchased a new stake in shares of Fate Therapeutics during the 4th quarter valued at $29,000. The Manufacturers Life Insurance Company purchased a new position in shares of Fate Therapeutics in the 4th quarter worth about $35,000. Finally, Russell Investments Group Ltd. grew its position in Fate Therapeutics by 73.1% during the third quarter. Russell Investments Group Ltd. now owns 28,676 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 12,114 shares during the period. 97.54% of the stock is owned by institutional investors and hedge funds.
Fate Therapeutics Company Profile
Fate Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of first‐in‐class cellular immunotherapies for cancer and immune disorders. The company leverages its proprietary induced pluripotent stem cell (iPSC) platform to create off‐the‐shelf natural killer (NK) and T‐cell products designed to overcome limitations of donor‐derived approaches. Fate’s research aims to deliver therapies with consistent quality, increased potency and scalable manufacturing for broad patient access.
Central to Fate’s pipeline are multiple iPSC‐derived cell therapy candidates in active clinical development.
Read More
- Five stocks we like better than Fate Therapeutics
- HIVE Weaponizes Power for an AI Pivot
- A Deep Dive Into NVIDIA’s Latest Portfolio Moves
- Brady Corp Wires Up a Massive AI-Powered Breakout
- Why Home Depot’s Sell-Off Could Become a Huge Opportunity
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
